Knowledge Ecology International (KEI) submitted comments to the National Institutes of Health (NIH) on January 12, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like Tyrosine Kinase 3 (FLT3) Expressing Malignancies Using Natural Killer Cells (NK Cells) Transduced With Retroviral or Lentiviral Vectors.” The Federal Register notice (85 FR 84356) outlines one exclusive license and two co-exclusive licenses to Senti Bio for the same technologies, but with varied fields of use, all relating to chimeric antigen receptor (CAR)-based immunotherapy for FLT3-expressing cancers (for example acute myelogenous leukemia (AML) and chronic myeloid leukemia (CML).
KEI has previously commented on two Federal Register notices regarding proposed exclusive licenses to Senti Bio (available here and here), and asked the NIH several questions regarding these proposed licenses. The NIH clarified that that this notice was to modify a previously noticed and executed license with Senti Bio, and that this was the only license the NIH had executed with Senti Bio.
A PDF of KEI’s full comments is available here: KEI_NIH_Comments_Exclusive_License_Senti_Bio_12Jan2021